|1.||Bousquet, Jean: 2 articles (01/2006 - 01/2006)|
|2.||Tulupov, D A: 1 article (01/2015)|
|3.||Zaplatnikov, A L: 1 article (01/2015)|
|4.||Karpova, E P: 1 article (01/2015)|
|5.||Schuberth, Christine: 1 article (01/2011)|
|6.||Zillinger, Thomas: 1 article (01/2011)|
|7.||Barchet, Winfried: 1 article (01/2011)|
|8.||Lüdenbach, Bastian: 1 article (01/2011)|
|9.||Hartmann, Evelyn: 1 article (01/2011)|
|10.||Schlee, Martin: 1 article (01/2011)|
|1.||Respiratory Tract Infections (Respiratory Tract Infection)
01/01/2006 - "It is concluded that Ribomunyl((R)) is effective in preventing and reducing upper and lower respiratory tract infections in adults. "
01/01/2003 - "To review the efficacy of the ribosomal immunostimulant Ribomunyl in preventing upper and lower respiratory tract infections. "
07/01/2006 - "The goal of our study was to observe 30 children with recurrent respiratory tract infection, 17 boy and 13 girl, they were treated with Ribomunyl. "
12/01/2000 - "Meta-analysis of published clinical trials of a ribosomal vaccine (ribomunyl) in prevention of respiratory infections."
01/01/2006 - "Role of ribomunyl((r)) in the prevention of recurrent respiratory tract infections in adults : overview of clinical results."
01/01/2006 - "Thus, Ribomunyl stimulates both the innate and acquired immune systems and offers preventive efficacy against both bacterial and viral infections. "
01/01/1990 - "Respiratory symptoms improved from the first month in the Immucytal treated children, but not in the placebo group, with a reduction in the incidence of infections in the upper and lower airways. "
12/01/2000 - "To perform a meta-analysis using data from all clinical trials and studies of a ribosomal vaccine (Ribomunyl((R))) in order to estimate its overall effect on the number of infections and antibacterial courses used per person. "
01/01/1997 - "Ribomunyl was effective throughout the study period, starting from the first month of treatment: a mean of 1.0 +/- 1.1 recurrences was recorded in the Ribomunyl group as compared to 1.5 +/- 1.4 recurrences in the placebo group; this indicated one-third fewer infections (P = 0.001). "
01/01/2002 - "However, only Ribomunyl (Pierre Fabre Medicament) (containing membrane and ribosomal fractions from four bacterial strains) allowed the authors to obtain a significant enhancement of allostimulatory abilities and cytokine production by Dphi in the absence of active cellular infection. "
01/01/1997 - "A multicenter, double-blind, placebo-controlled study was conducted to investigate the efficacy of an immunostimulant, Ribomunyl, in the prevention of recurrences of infectious rhinitis in adults. "
01/01/1997 - "This trial involved 327 patients (168 Ribomunyl treated and 159 placebo cases) with an average of 4.3 +/- 1.8 rhinitis episodes per patient recorded during the year preceding the study. "
01/01/1997 - "Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. "
|4.||Chronic Disease (Chronic Diseases)
01/01/2015 - "It is shown that the application of the ribosomal vaccine ribomunyl causes a significant reduction in the occurrence of acute respiratory infections in the frequently ill children, lowers the frequency of exacerbation of chronic diseases of the upper respiratory tract, and allows to decrease the use of antibiotics. "
|1.||Anti-Bacterial Agents (Antibiotics)
|4.||Interleukin-6 (Interleukin 6)
|6.||Interleukin-1beta (Interleukin 1 beta)
|7.||Interleukin-12 (IL 12)
|8.||Interleukin-8 (Interleukin 8)
|9.||Interleukin-4 (Interleukin 4)